Posts by Aparna R. Parikh, MD
-
Liquid Biopsy Outperforms Standard Biopsy for Characterizing Acquired Resistance in Gastrointestinal Cancers
In patients whose cancer progressed on targeted therapy, analysis of circulating tumor DNA in a blood sample ("liquid biopsy") was superior to tissue biopsy for identifying heterogeneous resistance alterations critical to the selection of subsequent therapy, according to research at the Mass General Cancer Center.
Biography
Dr. Parikh is an expert in Gastrointestinal Cancers with a focus on Young Adults with Colorectal Cancer. Her clinical practice is comprised primarily of patients with colorectal cancer and pancreatic cancer. She is a member of the NCCN guidelines for Colorectal Cancer. She had a robust clinical trial portfolio with the hopes of bringing novel agents into the clinic, working closely with laboratory collaborators at MGH. She also leads the clinical liquid biopsy efforts for the GI Oncology group and is an international expert in liquid biopsies helping to develop these tools in the setting of residual disease after curative intent surgeries, to understand response to treatment and to understand drug resistance. Though she is a clinical translational researcher, she also has a passion and background in cancer care in low and middle-incomes countries and does work that supports access, equity and education in LMICs and as the Director of the Global Cancer Care Program at MGH.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
